In summary, our data show that combination therapy with a β-AR blocker and an ACEi induces a switch in the activity of multiple kinase signaling pathways affected by TAC-induced HF, beyond those well known as directly initiated by the specific transmembrane receptors. The gene discussed is NRP1; the disease is hydrops fetalis.